All In Biotech

Drug Trial Radar · NCT06289673

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

INITIALL: Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

850

Planned (sponsor's estimate)

Start

Dec 26, 2024

Primary completion

May 2034

Study completion May 2039

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies. * To develop a central database of genomic and clinical findings. Secondary Objectives * To assess event free and overall survival data of patients enrolled on this study.

Conditions

  • Acute Lymphoblastic Leukemia
  • Lymphoblastic Lymphoma
  • Mixed Phenotype Acute Leukemia

Interventions

  • DexamethasoneDrug

    Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7

  • VincristineDrug

    Intravenously (IV) for 1 dose on Day 1 or 2

  • DaunorubicinDrug

    Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)

  • Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)Drug

    Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6

  • MethotrexateDrug

    Given IT as part of Intrathecal triple therapy.

  • CytarabineDrug

    Given IT as part of Intrathecal triple therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sufficient phenotypic and/or genomic data necessary for therapeutic protocol assignment by Day 8 (completion of INITIALL therapy).Time frame: 1 week from study entry
  2. Complete data within the INITIALL databaseTime frame: 3 months, 1 year, 3, 5 years from study entry

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Rady Children's Hospital

    San Diego, California · Recruiting

  • Our Lady of the Lakes Regional Medical Center

    Baton Rouge, Louisiana · Recruiting

  • Novant Health Presbyterian Hemby Children's Hospital

    Charlotte, North Carolina · Recruiting

  • Saint Francis Children's Hospital

    Tulsa, Oklahoma · Recruiting

  • St. Jude Children's Research Hospital

    Memphis, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.